Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020
10/19/2020 - 04:05 PM
DUBLIN , Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third quarter financial results on Monday, November 2, 2020 , after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST /9:30 p.m. GMT to discuss third quarter 2020 financial results and provide a business and financial update.
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.
Audio webcast/conference call: U.S. Dial-In Number: +1 855 353 7924 International Dial-In Number: +1 503 343 6056 Passcode: 2756835
A replay of the conference call will be available through November 9, 2020 and accessible through one of the following telephone numbers, using the passcode below: Replay U.S. Dial-In Number: +1 855 859 2056 Replay International Dial-In Number: +1 404 537 3406 Passcode: 2756835
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Jazz Pharmaceuticals Contacts:
Investors: Kathee Littrell Vice President, Investor Relations Ireland, +353 1 634 7887 U.S., +1 650 496 2717
Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Ireland, +353 1 697 2141 U.S., +1 215 867 4910
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2020-third-quarter-financial-results-on-november-2-2020-301155061.html
SOURCE Jazz Pharmaceuticals plc
JAZZ Rankings
#2855 Ranked by Stock Gains
JAZZ Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Ireland
City
Dublin
About JAZZ
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni